Updates in the Treatment of HER2+ Metastatic Breast Cancer

Discussion of recent clinical trial updates in HER2-positive metastatic breast cancer and implications for managing 2 patient case scenarios.

EP. 1: Preferences for Treating Relapsed HER2+ MBC

December 1st 2021

A panel of breast oncologists highlight their therapy preferences for a woman with HER2-positive metastatic breast cancer previously treated with docetaxel-trastuzumab-pertuzumab followed by paclitaxel and cisplatin.

EP. 2: Treatment Sequencing Strategies in HER2+ MBC

December 1st 2021

Treatment algorithms used in clinical practice by breast oncologists to best approach and subsequently treat patients with HER2-positive metastatic breast cancer.

EP. 3: Implications of HER2CLIMB Updates on Treating HER2+ MBC

December 6th 2021

Key takeaways from updates to the HER2CLIMB study in HER2-positive metastatic breast cancer.

EP. 4: Notable Treatment Advances in HER2+ MBC

December 6th 2021

Reactions to presentations from ESMO 2021 that demonstrated the potential of various new treatment approaches for use in HER2-positive metastatic breast cancer.

EP. 5: Treating After T-DM1 in Relapsed/Refractory HER2+ MBC

December 15th 2021

Recommendations regarding how to best treat a patient with HER2-positive metastatic breast cancer who has previously received multiple lines of therapy, including T-DM1.

EP. 6: Second-Line Treatment for HER2+ MBC

December 15th 2021

Variables that affect second-line treatment decisions in HER2-positive metastatic breast cancer.

EP. 7: Changing Treatment Paradigms in HER2+ MBC

December 22nd 2021

Expectations regarding future treatment guidelines in HER2-positive metastatic breast cancer as a result of therapeutic advances.

EP. 8: Understanding HER2 Expression in Metastatic Breast Cancer

December 22nd 2021

A small panel of breast oncologists recognize growing interest in understanding the role of HER2 expression in metastatic breast cancer.

EP. 9: The HER2+ MBC Treatment Pipeline

December 22nd 2021

Exciting therapeutic strategies in the HER2-positive metastatic breast cancer space that demonstrate potential in addressing gaps in treatment.

EP. 10: The Current Standard-of-Care for Patients with HER2+ Metastatic Breast Cancer

October 6th 2022

Neil M. Iyengar, MD briefly reviews the standard-of-care first-line treatment for patients with metastatic HER2+ breast cancer as well as historical approaches to progression after first-line treatment.